alpha-L-Fucp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp

Term ID

CHEBI:147486

Synonyms

(2S,3S,4R,5S,6S)-2-[(2R,3S,4R,5R)-5,6-dihydroxy-2-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
6-deoxy-alpha-L-galactopyranosyl-(1->4)-[beta-D-glucopyranosyl-(1->3)]-D-galactopyranose
alpha-L-fucopyranosyl-(1->4)-[beta-D-glucopyranosyl-(1->3)]-D-galactopyranose
beta-D-gluco-hexopyranosyl-(1->3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->4)]-D-galacto-hexopyranose
Glc(b1-3)[Fuc(a1-4)]Gal

Definition

A trisaccharide consisting of α-L-fucopyranose and β-D-galactose residues joined by a (1→4) glycosidic bond in which the hydroxy group at position 3 of the galactopyranose ring has been converted into the corresponding β-D-glucopyranosyl derivative.

References

glygen:G16882JV
glytoucan:G16882JV
kegg.glycan:G03328

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from alpha-L-Fucp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp

Phenotype where environments contain alpha-L-Fucp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp

Phenotype modified by environments containing alpha-L-Fucp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp

Phenotype affecting alpha-L-Fucp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp

Human Disease Model